Skip to main content

Cardiovascular regeneration

Edited by Ronald Li

An article collection in Stem Cell Research & Therapy.

This series reviews the current state-of-the-art stem cell-based approaches for disease modeling, drug discovery and myocardial repair, as well as the associated hurdles and potential solutions.

This series of articles has not been sponsored. All articles have undergone the journal’s standard peer review process. The Guest Editor and Editors declare no competing interests.

View all collections published in Stem Cell Research & Therapy

  1. Induced pluripotent stem cell-derived cardiomyocytes (iPS-CMs) may be suitable for myocardial repair. While their functional and structural properties have been extensively investigated, their response to isch...

    Authors: Andreja Brodarac, Tomo Šarić, Barbara Oberwallner, Shokoufeh Mahmoodzadeh, Klaus Neef, Julie Albrecht, Karsten Burkert, Matteo Oliverio, Filomain Nguemo, Yeong-Hoon Choi, Wolfram F Neiss, Ingo Morano, Jürgen Hescheler and Christof Stamm
    Citation: Stem Cell Research & Therapy 2015 6:83
    Content type: Research Published on:

  2. Heart disease remains the number one cause of death in developed countries. Loss of cardiomyocytes (CMs) due to aging or pathophysiological conditions (for example, myocardial infarction) is generally consider...

    Authors: Ronald A Li
    Citation: Stem Cell Research & Therapy 2014 5:141
    Content type: Editorial Published on:

  3. Human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) are the most promising source of cardiomyocytes (CMs) for experimental and clinical applications, but their use is largely limited by a structurall...

    Authors: Renjun Zhu, Adriana Blazeski, Ellen Poon, Kevin D Costa, Leslie Tung and Kenneth R Boheler
    Citation: Stem Cell Research & Therapy 2014 5:117
    Content type: Review Published on:

  4. Myocardial infarction is accompanied by a significant loss of cardiomyocytes (CMs). Functional CMs, differentiated from human embryonic stem cells (hESCs), offer a potentially unlimited cell source for cardiac...

    Authors: Alan Tin-Lun Lam, Allen Kuan-Liang Chen, Jian Li, William R Birch, Shaul Reuveny and Steve Kah-Weng Oh
    Citation: Stem Cell Research & Therapy 2014 5:110
    Content type: Research Published on:

  5. Human pluripotent stem cells (hPSCs), including embryonic and induced pluripotent stem cells, are abundant sources of cardiomyocytes (CMs) for cell replacement therapy and other applications such as disease mo...

    Authors: Wendy Keung, Kenneth R Boheler and Ronald A Li
    Citation: Stem Cell Research & Therapy 2014 5:17
    Content type: Review Published on:

  6. Although stem cell therapy is a promising treatment for myocardial infarction, the minimal functional improvements observed clinically limit its widespread application. A need exists to maximize the therapeuti...

    Authors: Kelly Elizabeth Sullivan, Kyle Patrick Quinn, Katherine Michele Tang, Irene Georgakoudi and Lauren Deems Black III
    Citation: Stem Cell Research & Therapy 2014 5:14
    Content type: Research Published on:

  7. Human pluripotent stem cell (hPSC)-derived cardiomyocytes have attracted attention as an unlimited source of cells for cardiac therapies. One of the factors to surmount to achieve this is the production of hPS...

    Authors: Allen Chen, Sherwin Ting, Jasmin Seow, Shaul Reuveny and Steve Oh
    Citation: Stem Cell Research & Therapy 2014 5:12
    Content type: Review Published on:

  8. Pluripotent stem cells (PSCs) represent an appealing source from which to develop cell replacement therapies. Different initiatives have been launched to promote their development toward clinical applications....

    Authors: Jean-Sébastien Hulot, Francesca Stillitano, Jo Elie Salem, Jason C Kovacic, Valentin Fuster and Roger J Hajjar
    Citation: Stem Cell Research & Therapy 2014 5:1
    Content type: Review Published on: